



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 72, 73

(48) Corrigendum issued on:
07.07.2021 Bulletin 2021/27

(45) Date of publication and mention
of the grant of the patent:
19.05.2021 Bulletin 2021/20

(21) Application number: **14764884.4**

(22) Date of filing: **17.03.2014**

(51) Int Cl.:
A61K 47/18 ^(2017.01) **A61K 47/22** ^(2006.01)
A61K 31/519 ^(2006.01) **A61K 9/08** ^(2006.01)
A61K 9/14 ^(2006.01) **A61P 19/06** ^(2006.01)
A61P 3/00 ^(2006.01) **A61K 9/00** ^(2006.01)
A61K 31/197 ^(2006.01) **A61K 31/198** ^(2006.01)
A61K 31/4188 ^(2006.01) **A61K 31/4415** ^(2006.01)
A61K 31/455 ^(2006.01) **A61K 31/51** ^(2006.01)
A61K 31/525 ^(2006.01) **A61K 31/593** ^(2006.01)
A61K 31/714 ^(2006.01) **A61K 31/375** ^(2006.01)

(86) International application number:
PCT/IB2014/001042

(87) International publication number:
WO 2014/140868 (18.09.2014 Gazette 2014/38)

(54) **XANTHINE OXIDASE INHIBITOR FORMULATIONS**
FORMULIERUNGEN FÜR XANTHINOXIDASEHEMMER
FORMULATIONS D'INHIBITEUR DE XANTHINE OXYDASE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **15.03.2013 US 201361790414 P**

(43) Date of publication of application:
06.04.2016 Bulletin 2016/14

(60) Divisional application:
21174259.8

(73) Proprietor: **XORTX Therapeutics Inc.**
Calgary, Alberta T2P 4K9 (CA)

(72) Inventors:
• **Allen, Davidoff**
Calgary, AB T3H 5Z7 (CA)
• **Boivin, Taryn**
Surrey, BC V4A 9W5 (CA)

(74) Representative: **Di Giovine, Paolo et al**
Società Italiana Brevetti S.p.A.
Piazza di Pietra, 38-39
00186 Roma (IT)

(56) References cited:
WO-A1-2006/083687 WO-A1-2007/044910
WO-A1-2011/097269 WO-A1-2012/098501
CA-A1- 2 519 126 US-A- 5 484 605
US-A- 5 661 154 US-B1- 6 544 726
US-B1- 6 569 862

- **AMMAR H O ET AL: "SOLUBILIZATION OF ALLOPURINOL WITH METHYL XANTHINES", DIE PHARMAZIE: AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES, GOVI VERLAG PHARMAZEUTISCHER VERLAG GMBH, DE, vol. 49, no. 11, 1 November 1994 (1994-11-01), pages 839-842, XP000476672, ISSN: 0031-7144**
- **Atsushi Hirano ET AL: "Arginine-Assisted Solubilization System for Drug Substances: Solubility Experiment and Simulation", The Journal of Physical Chemistry B, vol. 114, no. 42, 28 October 2010 (2010-10-28), pages 13455-13462, XP055046746, ISSN: 1520-6106, DOI: 10.1021/jp101909a**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).